Literature DB >> 15374853

Refractory adult onset Still's disease successfully treated with anakinra.

F M Vasques Godinho, M J Parreira Santos, J Canas da Silva.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374853      PMCID: PMC1755446          DOI: 10.1136/ard.2004.026617

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  31 in total

Review 1.  Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.

Authors:  R Goldbach-Mansky
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

Review 2.  Diagnosis and management of adult onset Still's disease.

Authors:  P Efthimiou; P K Paik; L Bielory
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

4.  Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.

Authors:  George D Kalliolias; Panagiotis E Georgiou; Ioannis A Antonopoulos; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Ann Rheum Dis       Date:  2007-06       Impact factor: 19.103

Review 5.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

6.  [Adult onset Still's disease].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

7.  [Recommendations on therapy using interleukin-1beta-blocking agents].

Authors:  B Manger; M Gaubitz; H Michels
Journal:  Z Rheumatol       Date:  2009-11       Impact factor: 1.372

Review 8.  Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses.

Authors:  Raphaela Goldbach-Mansky; Daniel L Kastner
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

Review 9.  Therapy of autoinflammatory syndromes.

Authors:  Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

Review 10.  Interleukin-1 function and role in rheumatic disease.

Authors:  Georg Schett; Jean-Michel Dayer; Bernhard Manger
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.